What is the recommended management for non‑alcoholic fatty liver disease (NAFLD)?

Management of Non-Alcoholic Fatty Liver Disease (NAFLD)

All NAFLD patients require lifestyle modifications including weight reduction, dietary control, and exercise, plus treatment of metabolic comorbidities—this is the cornerstone of therapy regardless of disease severity. 1

Risk Stratification Determines Treatment Intensity

The severity of liver fibrosis is the most critical prognostic factor, with stage ≥F2 fibrosis independently predicting liver-related complications and mortality 1. Treatment decisions must be based on whether patients have simple steatosis (NAFL), steatohepatitis (NASH), or significant fibrosis:

For All NAFLD Patients (Regardless of Severity)

Lifestyle modifications are mandatory for every patient: 1

• Weight Loss Targets:

  • 5-7% weight loss reduces intrahepatic fat content and inflammation 1
  • 7-10% weight loss improves hepatic inflammation and fibrosis 1

  • 10% weight loss achieves fibrosis improvement in 45% of patients 1

  • Progressive weight loss of <1 kg/week is recommended; rapid weight loss can worsen portal inflammation and fibrosis 1

• Dietary Interventions:

  • Mediterranean diet is the primary dietary recommendation, reducing liver fat more effectively than low-fat/high-carbohydrate diets 1
  • Reduce total energy intake by >500 kcal/day 1
  • Eliminate processed foods and beverages with added fructose 1
  • Replace saturated fats with PUFAs (especially omega-3) and MUFAs 1
  • Increase fiber intake through whole grains, vegetables, fruits, legumes, nuts, and seeds 1

• Exercise Requirements:

  • Minimum: moderate-intensity exercise for >30 minutes, >3 times per week 1
  • Optimal: 150-200 minutes/week of moderate-intensity aerobic activity in 3-5 sessions 1
  • Both aerobic exercise and resistance training effectively reduce liver fat; choice should be tailored to patient cardiopulmonary fitness and preferences 1
  • Vigorous exercise (running) provides greater benefit than moderate exercise (brisk walking) for NASH and fibrosis 1

• Alcohol Consumption:

  • Patients with NAFLD cirrhosis must abstain completely from alcohol to reduce HCC risk and liver-related mortality 1
  • Even light alcohol consumption (9-20 g/day) doubles the risk of adverse liver outcomes in NAFLD patients 1
  • Moderate or less alcohol use requires caution even in non-cirrhotic NAFLD 1

• Smoking Cessation:

  • Smoking increases HCC risk by 1.5-1.8 times and is associated with liver fibrosis 1
  • Smoking cessation is recommended for all NAFLD patients 1

Management of Metabolic Comorbidities

Aggressive treatment of diabetes, obesity, hypertension, and dyslipidemia is essential: 1

• Diabetes Management:

  • Metformin decreases HCC incidence 1
  • GLP-1 agonists are effective for NASH recovery 1
  • Avoid sulfonylureas and insulin when possible (increase HCC incidence by 1.6 and 2.6 times respectively) 1

• Dyslipidemia:

  • Statins are safe in NAFLD patients and reduce HCC risk by 37% 1
  • Statins should be used for standard cardiovascular indications 1

Pharmacologic Treatment for NASH with Fibrosis

Pharmacologic therapy should be reserved for patients with biopsy-proven NASH and significant fibrosis (≥F2) or high-risk features: 1

• Pioglitazone (30-45 mg/day):

  • Improves steatohepatitis histologically in patients with or without diabetes 1
  • Does not consistently improve liver fibrosis 1
  • Consider in patients with biopsy-proven NASH 1

• Vitamin E (800 IU/day):

  • Benefits select patients with biopsy-proven NASH 1
  • Primarily for non-diabetic patients with NASH 1

Important caveat: No drug is currently FDA-approved specifically for NASH, so all pharmacologic treatments are off-label 1. Metformin has scarce evidence for histological efficacy in NASH and is not recommended as liver-directed therapy 1.

Surveillance for Patients with NAFLD Cirrhosis

Patients with NAFLD cirrhosis require HCC surveillance: 1

• Abdominal ultrasound every 6 months is the primary surveillance test 1
• In overweight/obese patients where ultrasound is technically difficult, use CT or MRI instead 1
• Esophagogastroduodenoscopy screening for esophageal varices per standard cirrhosis guidelines 1

Patients Without NASH or Significant Fibrosis

Patients with simple steatosis (NAFL) without fibrosis should receive only lifestyle counseling—no pharmacotherapy for their liver condition: 1

This stratified approach prioritizes morbidity and mortality reduction by focusing intensive interventions on those at highest risk while avoiding unnecessary pharmacologic treatment in low-risk patients.